FIGO Classification of Fibroid, Myoma, Uterine Fibroids, Cervical, Ovarian & Endometrial Cancer

FIGO Classification of Fibroid, Myoma, Uterine Fibroids, Cervical, Ovarian & Endometrial Cancer:

1. What is FIGO Classification of Fibroid?

2. FIGO Classification of Myoma

3. FIGO Classification of Uterine Fibroids

4. FIGO Classification of Cervical Cancer

5. FIGO Classification of Ovarian Cancer

6. FIGO Classification of Endometrial Cancer

What is FIGO Classification of Fibroid?

The FIGO classification of fibroid is a medical system used to describe the exact location of a fibroid in relation to the uterine cavity, uterine muscle wall, and outer uterine surface. FIGO stands for the International Federation of Gynecology and Obstetrics. In simple words, this system helps doctors explain whether a fibroid is inside the uterine cavity, within the muscular wall, outside the uterus, or in an unusual location such as the cervix. This matters because the same-sized fibroid can cause very different symptoms depending on where it grows. A small fibroid pressing into the uterine cavity may cause heavy bleeding or infertility concerns, while a larger outer fibroid may mainly cause pressure, pelvic heaviness, or urinary frequency.

The FIGO fibroid system usually describes fibroids from Type 0 to Type 8. Type 0, 1, and 2 are mostly submucosal fibroids, meaning they are close to or projecting into the uterine cavity. Type 3 touches the endometrium but remains inside the muscle wall. Type 4 is completely intramural, while Type 5, 6, and 7 are closer to the outer uterine surface. Type 8 is used for other special locations, such as cervical or parasitic fibroids. This classification is useful for ultrasound, MRI reporting, fertility planning, hysteroscopic surgery, myomectomy, and uterine artery embolization. Key points include:

• Type 0–2: commonly linked with heavy bleeding and cavity distortion.
• Type 3–4: mainly within the uterine muscle wall.
• Type 5–7: closer to the outer uterine surface.
• Type 8: unusual locations such as cervical fibroid.

FIGO Classification of Myoma

A myoma is another common name for a uterine fibroid, and it is also called a leiomyoma. Therefore, the FIGO classification of myoma follows the same location-based pattern used for fibroids. The word “myoma” may sound more technical, but it usually refers to a benign growth arising from the smooth muscle layer of the uterus. These growths are not the same as cancer, although they can create significant symptoms in some women. The FIGO system is helpful because it avoids vague descriptions such as “small fibroid” or “large fibroid” only. Instead, it explains the anatomical relationship of the myoma to the endometrial cavity and the outer uterine surface.

For example, a FIGO Type 1 myoma means the lesion is submucosal with less than half of it extending into the uterine muscle wall. A FIGO Type 2 myoma has a greater intramural component, while Type 4 is completely within the muscle wall. This type of description is especially important when a patient has symptoms such as heavy menstrual bleeding, pelvic pain, recurrent miscarriage, anemia, or infertility. A doctor may choose hysteroscopic removal for some submucosal myomas, while deeper intramural or subserosal myomas may require different treatment planning. In blog-writing terms, the main message is simple: FIGO classification tells where the myoma is, not whether it is dangerous by itself.

FIGO Classification of Uterine Fibroids

Uterine fibroids are among the most common benign tumors of the uterus, and the FIGO system gives a structured way to describe them. Many women have fibroids without symptoms, while others experience heavy periods, prolonged bleeding, pelvic pressure, backache, bloating, urinary frequency, constipation, or fertility-related concerns. The term “uterine fibroids” is broad, so classification becomes important. A report that says “uterine fibroid present” is less helpful than a report that says “FIGO Type 2 submucosal fibroid” or “FIGO Type 6 subserosal fibroid.” The second description immediately tells the clinician how the fibroid is positioned and what kind of symptoms or treatment challenges may be expected.

The main FIGO uterine fibroid categories can be remembered by location. Submucosal fibroids are near the uterine lining and may interfere with bleeding patterns or embryo implantation. Intramural fibroids are located in the muscular wall and may enlarge the uterus or cause pressure. Subserosal fibroids grow toward the outside of the uterus and may press on nearby organs. Pedunculated fibroids are attached by a stalk, either inside the cavity or outside the uterus. Hybrid fibroids can involve more than one zone, such as a lesion extending from the inner side toward the outer side. This is why FIGO classification is widely used in imaging and gynecology: it turns a confusing condition into a clearer map for diagnosis, counseling, and treatment planning.

FIGO Classification of Cervical Cancer

The FIGO classification of cervical cancer is different from the FIGO fibroid system because cancer staging is not based on benign tumor location alone. Instead, cervical cancer staging describes how far the cancer has spread. In general, early stages are limited to the cervix, while advanced stages involve nearby tissues, pelvic wall, lymph nodes, bladder, rectum, or distant organs. FIGO cervical cancer staging is important because treatment decisions often depend on the stage. For example, very early disease may be treated surgically in selected patients, while locally advanced disease often requires chemoradiation. This is why staging is a central part of cervical cancer management.

The revised cervical cancer FIGO staging system allows doctors to use clinical examination, imaging, and pathology when available. This is important because MRI, CT, PET scans, and biopsy-based information can improve assessment of tumor size, local spread, and lymph node involvement. In simplified form, Stage I means cancer is confined to the cervix, Stage II means it has extended beyond the uterus but not to the pelvic wall or lower vagina, Stage III includes pelvic wall involvement, lower vaginal involvement, kidney-related obstruction, or lymph node disease, and Stage IV means invasion of bladder or rectal mucosa or distant spread. For readers, the key point is that FIGO cervical cancer staging helps estimate severity, guide treatment, and discuss prognosis.

FIGO Classification of Ovarian Cancer

The FIGO classification of ovarian cancer is used to stage cancers that arise from the ovary, fallopian tube, and primary peritoneum. These cancers are often grouped together because they may behave similarly and may be discovered after spread within the abdomen. Unlike fibroids, which are benign and classified by uterine location, ovarian cancer is staged by the extent of disease. Stage I generally means the cancer is limited to the ovary or fallopian tube. Stage II means spread within the pelvis. Stage III usually means spread to the abdominal lining outside the pelvis and/or nearby lymph nodes. Stage IV indicates distant metastasis, such as spread inside the liver or outside the abdominal cavity.

Ovarian cancer staging is especially important because symptoms can be vague in earlier stages. Bloating, pelvic discomfort, early fullness after eating, urinary changes, and abdominal swelling can be caused by many non-cancerous conditions, so staging only happens after proper medical evaluation. Surgery often plays a major role in diagnosis and staging because the abdomen and pelvis may need careful assessment. The FIGO system helps doctors communicate disease extent in a standardized way, compare outcomes, plan chemotherapy, and decide whether additional targeted treatment may be considered. For a Blogger article, the simple explanation is this: FIGO ovarian cancer staging tells how far the cancer has traveled from its starting point, which is crucial for treatment planning and prognosis discussion.

FIGO Classification of Endometrial Cancer

The FIGO classification of endometrial cancer applies to cancer that starts in the lining of the uterus, called the endometrium. This condition is different from fibroids and myomas because fibroids are benign muscle tumors, while endometrial cancer is malignant disease of the uterine lining. FIGO staging for endometrial cancer considers how deeply the cancer invades the uterus, whether it reaches the cervix, whether it spreads to pelvic or para-aortic lymph nodes, and whether it moves to abdominal or distant sites. Early-stage disease is often limited to the uterus, while more advanced stages involve regional spread or distant metastasis.

Modern endometrial cancer staging has become more detailed because doctors now consider not only anatomy but also tumor type, grade, and molecular features in many settings. This reflects a better understanding that two tumors with a similar location may behave differently biologically. Symptoms often include abnormal uterine bleeding, postmenopausal bleeding, pelvic pain, or unusual discharge, but proper diagnosis requires medical assessment, imaging, and tissue sampling. The purpose of the FIGO system is to create a shared language between gynecologists, oncologists, radiologists, pathologists, and patients. In simple words, FIGO endometrial cancer classification helps explain the stage, risk pattern, and treatment direction, making it an essential part of cancer care planning.